Raia Drogasil S.a. · BMFBOVESPA:RADL3
Raia Drogasil — Q3 2025 Earnings Presentation
16 slides from Raia Drogasil's earnings presentation, Nov 6, 2025
Slide 1: Earnings Presentation 3Q25
<}RDsatide <>DROGASIL | <> Raia
Slide 2: Legal Warning
Legal Warning The material that follows is a presentation of general background information about Raia Drogasil S.A. (the “Company”) as of the date of the presentation. It is information in summary form and does not purport to be complete. It is not intended to be relied upon as advice to potential
Slide 3: Operational Highlights
OPERATIONAL PHARMACIES: 3,453 units in operation (88 openings and 6 closures); CUSTOMERS: 51.0 MM active customers in the last 12 months; TICKETS & NPS: 111.6 MM tickets in the quarter with an NPS of 91. GROSS REVENUE: R$ 12.1 B, +12.7% consolidated, +15.5% in retail, with a +4.8 pp real MSSS gain;
Slide 4: Consolidated gross revenue and sales mix
10.804 Consolidated gross revenue of R$ 12.1 B with +15.5% growth in retail. Prescription 9.552 9.824 9.961 9.948 medicine was the highlight, in addition to the continued acceleration in HPC. 2T24 3T24 4T24 1T25 2T25 Consolidated gross revenues Sales mix R$ millions Retail, per product category RD E
Slide 5: Mature Store Growth
Mature store growth of 7.8%, 4.8 pp above the CMED price adjustment of 3,1% and 2.6 pp above the CPI of 5.2%. Positive calendar effect of 0.3 pp. Revenue growth Same-Store sales growth Mature-Store sales growth Consolidated Retail Retail 7.8% 9.7% 15.9% 9.1% 6.7% 13.9% 7.9% 5.6% 7.3% 5.5% 12.7% 2.2%
Slide 6: Digital Growth and Penetration
Digital grew 62% to R$ 3.0 B in the 3Q25. Penetration reached 26.7%, with 97% of orders delivered or collected in under 60 minutes. Digital sales Digital channel mix Delivery mix R$ million, % of retail gross revenue % of digital sales, 3Q25 % of digital sales, 3Q25 26.7% * Super Desktopapps Super 2
Slide 7: Market Share by Region
13% 8% 9% 18% 15% 14% We continue to capture market share in all 21% regions of Brazil 12% 11% with a national gain 20% of 0.8 pp, maintaining the diversification and 14% guidance 11% 17% 16% of16% 330-350 stores. 20% 17% 15% 13% 20% 10% 17% 19% 40% 29% 34% 25% Market share Pharmacies per region 18%
Slide 8: Gross Margin
Gross mg. of 27.4% (-0.2 pp from one-off ICMS gains in the 3Q24). Pressures from pricing and GLP-1 mix offset by investees, NPV adj., inventory losses and others. Gross profit* R$ millions, % of gross revenue 27.6% 27.6% 27.4% 27.4% 26.6% 3,314.4 3,198.6 2,970.7 2,994.1 2,881.3 3Q24 4Q24 1Q25 2Q25 3
Slide 9: Selling and G&A Expenses
Selling expenses of 17.3%, +0.2 pp vs. the 3Q24. -0.2 pp normalized for personnel. G&A of 2.6%, a structural dilution of 0.4 pp. Selling expenses General and administrative expenses R$ millions, % of gross revenue R$ millions, % of gross revenue 3.3% 18.0% 17.9% 3.0% 2.8% 17.3% 17.3% 17.1% 363.5 2.6
Slide 10: EBITDA and Cash Cycle
9.552 EBITDA 9.824 9.961of 9.948 R$ 909 MM, +12.2% with a stable margin of 7.5%. +0.6 pp excluding 10.804 one-off ICMS/personnel 3Q24 effects. Cash cycle improvement of 3.0 days. 2T24 3T24 4T24 1T25 2T25 Adjusted EBITDA Historical adjusted EBITDA* Cash cycle** R$ millions, % of gross revenue % of gr
Slide 11: Financial Expenses and Net Income
Financial expenses of 1.6% and effective tax rate of 11.5%. Net income of R$ 402 MM, a 19.3% growth. Net margin of 3.3%, a 0.2 pp expansion. Financial expenses Effective tax rates* Adjusted net income* R$ millions, % of gross revenue R$ millions, % of gross revenue R$ millions, % of gross revenue Ef
Slide 12: Free Cash Flow and Leverage
Free cash flow of R$ 648 MM, with R$ 558 MM in total cash generation. Financial leverage of 1.1x LTM EBITDA. Cash flow (R$ millions) 3Q25 3Q24 Adjusted EBIT 643.3 579.2 Net debt and financial leverage R$ millions, as a ratio of LTM adjusted EBITDA NPV adjustment (69.8) (47.1) Non-recurring expenses
Slide 13: Building the Future with Consistency
Building the Future with Consistency. A compounder in Pharma Retailing. CONSISTENT EXECUTION AND SUSTAINABLE GROWTH FINANCIAL ROBUSTNESS & CASH GENERATION Robust growth with MSSS acceleration Robust free cash flow HPC acceleration Improved cash cycle & inventory days Authority in GLP-1 Controlled le
Slide 14: RD Saúde
RDsatde 4SDROGASIL | <> Raia
Slide 15: RD Saúde Day
We will host our Investor Day on December 1st. RD Save the date to keep up with our next steps in a journey towards a 01 Saúde healthier society. DEC Day RD Saúde Campus Av. Corifeu de Azevedo Marques, 3.097, Butantã - São Paulo / SP We recommend the use of transportation apps. 2pm Welcome Coffee 2:
Slide 16: Thank You
Thank you!